Evaluation of Postoperative Cognitive Function, Anxiety, Depression and Quality of Life in Patients With Unruptured Intracranial Aneurysms
8 de mayo de 2018 actualizado por: Jun Wang, Xuanwu Hospital, Beijing
Evaluation of Postoperative Cognitive Function, Anxiety, Depression and Quality of Life in Patients With Unruptured Intracranial Aneurysms: a Multi-center Prospective Cohort Study
This prospective single-center cohort study aims to identify the incidence of cognitive dysfunction after unruptured aneurysm operation and explore the influencing factors.
The primary end point is the cognitive dysfunction at 6 months after operation.The features of cognitive function, mental status, neurological function recovery, and quality of life of patients with unruptured intracranial aneurysms at different time points would be analyzed.
Descripción general del estudio
Estado
Desconocido
Condiciones
Descripción detallada
This main topics is to identify and screen the patients with unruptured aneurysm who likely to suffer from cognitive dysfunction.
All examinations were administered by a trained neuropsychologist.The assessment of cognitive function and mental state would be performed before operation and 6 months after operation, with the use of Montreal Cognitive Assessment Scale (MoCA) for the cognitive function, the Hamilton Anxiety Scale (HAMA) and the Hamilton Depression Scale (HDMA) tests for the mental state.
The Cognitive dysfunction at 6 months after operation would be the primary end point, and the underlying factors responsible for the declined cognitive function would be analyze.
The assessment of neurological function and quality of life would be performed before operation,3 months after operation and 6 months after operation, with the use of the Modified Rankin Scale(mRS) and the Functional Activities Questionnaire(FAQ) for the neurological function, the Richards-Campbell Sleep Questionnaire(RCSQ) and the 36-item short from health survey(SF-36) tests for the quality of life.
Tipo de estudio
De observación
Inscripción (Anticipado)
350
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
14 años y mayores (Niño, Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra de probabilidad
Población de estudio
the patients with unruptured intracranial aneurysms who treated in neurosurgery at Xuanwu Hospital
Descripción
Inclusion Criteria:
- At least one imaging (CTA / MRI / DSA) study to confirm unruptured intracranial aneurysms for the patients who would undergo surgical treatment for the first time.;
- Patients who live independent with minimal care support, mRS score ≤3 points;
- Age > 14 years old;
- Han ethnicity, Right handed, can complete the test;
- Patient or family agrees to sign informed consent.
Exclusion Criteria:
- Other cerebrovascular diseases，such as ischemic stroke, arteriovenous malformation, etc;
- With an unexplained subarachnoid hemorrhage;
- History of Neurological disease surgery;
- Previous psychiatric and dementia history that cannot communicate with other people;
- Patients who refused to follow up.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
the Incidence of cognitive dysfunction at 6 months after operation
Periodo de tiempo: the 6th month after operation of the patient inclusion in the study
|
The Montreal Cognitive Assessment Scale (MoCA) scale contains 8 cognitive domain,11 items and is suitable for assess cognitive function which including: Attention and concentration, executive function, memory, language, visual structure skills, abstract thinking, calculation and orientation.. 1 point for each correct answer.
No points if they make any errors.
The total score is 30 points.
For those who have been educated for 12 years or less and the total score of MoCA is less than 30, one point is added to the total MoCA score.
According to the results of MoCA assessment, Patients were divided into two groups: cognitive dysfunction group and cognitive function normal group.
MoCA score ≥26 points suggested normal cognitive function (CN).
|
the 6th month after operation of the patient inclusion in the study
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
the difference in the percentage of patients with HAMA score ≥14 before operation and 6 months after operation
Periodo de tiempo: before operation and the 6th month after operation of the patient inclusion in the study
|
The Hamilton Anxiety Scale (HAMA) scale contains 14 items and is suitable for the adults with anxiety.
Each item is divided into 5 grades evaluated using 0 to 4 scores.
The total scores of HAMA scale can reflect patients' anxious condition to some extent.
The total scores of less than 7 is regarded as no anxiety, 7 or more possible anxiety, 14 or more definite anxiety, 21 or more marked anxiety, 29 or more severe anxiety.
In this study, Anxiety is defined as≥14 points.
|
before operation and the 6th month after operation of the patient inclusion in the study
|
|
the difference in the percentage of patients with HDMA score ≥14 before operation and 6 months after operation
Periodo de tiempo: before operation and the 6th month after operation of the patient inclusion in the study
|
The Hamilton Depression Scale (HAMD) scale contains 24 items and is suitable for the adults with depression.
Each item is divided into 5 grades evaluated using 0 to 4 scores.
The total scores of the HAMD scale can reflect patients' depressive condition to some extent.
The total scores of less than 8 is regarded as no depression, 8 to 16 mild depression, 17 to 24 moderate depression, and more than 24 severe depression.
In this study, Depression is defined as≥14 points.
|
before operation and the 6th month after operation of the patient inclusion in the study
|
|
the tendency of mRS scores and the difference in the percentage of patients with mRS scores 0-3 and 4-6 points before operation, 3 months after operation, and 6 months after operation
Periodo de tiempo: before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
The Modified Rankin Scale (mRS) is a valid and clinically relevant instrument that is used to assess recovery (death, disability, and dependence) after stroke and is a commonly used outcome measure in SAH studies.
The mRS ranges from 0 (no symptoms) to 6 (death).
Unfavourable outcome in survivors is defined as mRS 3-5.
|
before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
|
the tendency of SF-36 scores before operation, 3 months after operation, and 6 months after operation
Periodo de tiempo: before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
36-item short form health survey(SF-36)
|
before operation ,the 3th month and the 6th month after operation of the patient inclusion in the study
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Silla de estudio: Jun Wang, Master, Xuanwu Hospital, Beijing
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Anticipado)
1 de mayo de 2018
Finalización primaria (Anticipado)
1 de febrero de 2020
Finalización del estudio (Anticipado)
1 de mayo de 2020
Fechas de registro del estudio
Enviado por primera vez
3 de abril de 2018
Primero enviado que cumplió con los criterios de control de calidad
3 de abril de 2018
Publicado por primera vez (Actual)
11 de abril de 2018
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
9 de mayo de 2018
Última actualización enviada que cumplió con los criterios de control de calidad
8 de mayo de 2018
Última verificación
1 de mayo de 2018
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- UIACGF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .